Previous Close | 5.11 |
Open | 6.30 |
Bid | 5.85 |
Ask | 7.20 |
Strike | 34.00 |
Expire Date | 2024-12-20 |
Day's Range | 6.30 - 6.30 |
Contract Range | N/A |
Volume | |
Open Interest | 32 |
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.